Phase 1/2 biotech developing precision T cell therapies for solid tumors.
Industry: Health Care
First Day Return: -8.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 03/01/2021 |
Offer Price | $18.00 |
Price Range $17.00 - $19.00 | |
Offer Shares (mm) | 9.8 |
Deal Size ($mm) | $176 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 03/30/2021 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $176 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | London, United Kingdom |
Founded | 2016 |
Employees at IPO | 159 |
Website www.achillestx.com |